![[Feature stock] HLB, lower limit price due to news of non-approval of new liver cancer drug in US (comprehensive)](https://img.yna.co.kr/photo/cms/2023/10/28/04/PCM20231028000004017_P2.jpg)
[Feature stock] HLB, lower limit price due to news of non-approval of new liver cancer drug in US (comprehensive)
⚡ Quick Summary
(Seoul = Yonhap News) Reporter Lim Eun-jin = The price of a new drug promoted by HLB [028300] plummeted to the limit on the 10th due to the news that it had failed to obtain product approval in the United States.
🗞️ 4 sources covered this story
[Breaking News] Supreme Court, ruling on Kim Kun-hee’s ‘Deutsche stock price manipulation’ case on the 16th
KhanReasons why now is a good time to eat onions due to lower prices... Health benefits noted by researchers
Khan[Breaking News] SK Hynix ADR public offering price confirmed at $149... Highest ever foreign company IPO
경향신문
[Breaking News] SK Hynix ADR public offering price confirmed at $149... Highest ever foreign company IPO
Khan📰 Related Articles
Coupang also participates in simple payment… ‘Rocket Pay’ launched in the second half of the year
Yonhap
‘Workout begins’ JoongAng Ilbo “Promised self-rescue plan implemented without disruption”
Yonhap
Lee Jong-hwa, a former professor at the National Police University who is an expert in crisis negotiation and ambassador to Argentina (comprehensive)
Yonhap“Local currency performance bonus? Get it from the National Assembly members” Park Min-gyu, in anger, eventually withdraws the bill
한겨레